NEW!

More documents

Recommendations

Info

Thursday, April 21 Poster Session 8:30 a.m.–5:30 p.m. P6.167 Real-World Patient Retention and Satisfaction on Fingolimod Versus Platform Injectable Disease-Modifying Therapies in Early Relapsing-Remitting Multiple Sclerosis; Results from PREFERMS —Heidi Crayton, Brian Steingo, Deren Huang, Xiangyi Meng, Lesley Schofield, Kristen Johnson, Nadia Tenenbaum P6.168 Efficacy and Tolerability of Fingolimod, Dimethylfumarate, and Teriflunomide in Patients with Multiple Sclerosis: Real World Experience from a Single Center —NgocHanh Vu, Michael Bradshaw, Harold Moses, Subramaniam Sriram, Siddharama Pawate P6.169 Early Clinical Efficacy of Fingolimod Compared with Interferon Beta-1a in Relapsing Multiple Sclerosis — Barry Singer, Daniel Ontaneda, Xiangyi Meng, Kathleen Hawker P6.170 Comparison of Baseline Characteristics of Glatiramer Acetate Versus Fingolimod in Multiple Sclerosis Patients on Brain Volume, Cognition and Neuro-QOL Outcomes: Preliminary Analysis of a Longitudinal Observational Study —Justin Honce, Kavita Nair, Brian Hoyt, Stefan Sillau, Brittany Wedeman, Eric Engebretson, Brandi Vollmer, Kristen Johnson, Nadia Tenenbaum, Vivian Herrera, Lisa Siconolfi, Augusto Miravalle, Jeffrey Bennett, John Corboy, Timothy Vollmer, Enrique Alvarez P6.171 Teriflunomide Exhibits Similar Results to Fingolimod in Number Needed to Treat Analysis —Thomas Leist, Aaron Miller, Karthinathan Thangavelu, Steven Hass, Mark Freedman P6.172 Clinical Effectiveness and Impact on Patient-Reported Outcomes of Delayed-Release Dimethyl Fumarate in Relapsing Multiple Sclerosis Patients After Suboptimal Response to Glatiramer Acetate: Six-Month Interim Analysis of a Prospective, Multicenter, Open- Label, Single-Arm, Observational Study (RESPOND)—Kiren Kresa-Reahl, Pavle Repovic, Derrick Robertson, Macaulay Okwuokenye, Leslie Meltzer, Monica Mann P6.173 Number Needed to Treat Analysis Comparing Teriflunomide and Injectable Disease-Modifying Therapies —Thomas Leist, Aaron Miller, Karthinathan Thangavelu, Steven Hass, Mark Freedman P6.174 Predictors of Long-Term Interferon Discontinuation in Newly Diagnosed Relapsing Multiple Sclerosis — Marcello Moccia, Raffaele Palladino, Roberta Lanzillo, Vincenzo Brescia Morra P6.175 Prevalence and Factors Leading to Unemployment in Immunomodulatory Treated and Untreated MS Patients in Poland - Preliminary Report —Dorota Koziarska, Danuta Nocon, Slawomir Wawrzyniak, Alina Kułakowska, Monika Adamczyk-Sowa, Król Joanna, Małgorzata Szcześniak, Przemyslaw Nowacki P6.176 Differences in Work Productivity Activity Impairment in MS Patients Initiated on Oral DMF Versus Interferon Beta or Glatiramer Acetate in Europe and the US —Ravi Iyer, Eddie Jones, Michael Edwards, Andrew Lee, James Pike P6.177 Is Severity of Adverse Events Affected by The Dose and Frequency of Glatiramer Acetate Treatment of Relapsing-Remitting Multiple Sclerosis? —Francisco Zagmutt, Ying Wu, Augusto Grinspan, Scott Kolodny, Sanjay Gandhi P6.178 Real-World Assessment of Relapse Rates in Patients with Multiple Sclerosis Newly Initiating Subcutaneous Interferon β-1a Vs Oral Disease-Modifying Drugs —Chris Kozma, Frederick Munschauer, Amy Phillips P6.179 Change in the Therapeutic Management of Multiple Sclerosis with Selective Immunosuppressants and Its Influence on the Clinical Course of the Disease —Jose E Meca-Lallana, Rocio Hernandez-Clares, Ester Carreón-Guarnizo, María Cardán-Sánchez, Cristina Sánchez- Vizcaíno Buendía, Judith Jimenez-Veiga, Adelaida Leon-Hernández, Gema Salgado- Cecilia, Jose Javier Martín-Fernández P6.180 Natalizumab, First Therapy to Demonstrate a Significant Impact on Multiple Sclerosis Disease Severity — Francois Jacques, Victorine Sikati Foko, Jacynthe Fortin P6.181 Real World Relapse Rates of Glatiramer Acetate Patients Switching to Fingolimod or Interferon Beta-1a Versus Remaining on Glatiramer Acetate — Yunfeng Li, Tara Nazareth, Huanxue Zhou, Kristen Johnson, John Ko, Kathleen Hawker, Vivian Herrera, Rahul Sasane P6.182 Longitudinal Analysis of Anti-JCV Antibody Index in Natalizumab- Treated Multiple Sclerosis Patients —Iain McGurgan, Andrew Lockhart, Michael Hutchinson, Christopher McGuigan P6.183 RRMS Patients Switching from SC IFNB-1a to Alemtuzumab in the CARE-MS I and II Extension Study Have a Reduced Rate of Brain Volume Loss — Frederik Barkhof, Jeffrey Cohen, Alasdair Coles, Edward Fox, Hans-Peter Hartung, Eva Havrdova, Krzysztof Selmaj, David Margolin, Karthinathan Thangavelu, Douglas Arnold P6.184 Safety and Efficacy of Alemtuzumab After Switching from Fingolimod: A German Multi-Center Experienceover One Year —Ralf Linker, Antonios Bayas, Anna Constantinidis, Sebastian Doerck, Kerstin Hellwig, Christoph Kleinschnitz, Ingo Kleiter, De-Hyung Lee, Mathias Maurer, Ralf Gold P6.185 Safety of Using Disease- Modifying Therapy Post-Alemtuzumab Treatment in Patients with Active Relapsing-Remitting Multiple Sclerosis in the Alemtuzumab Clinical Development Program —Ann Bass, Keith Edwards, Bhupendra Khatri, Krzysztof Selmaj, David Margolin, Linda Kasten, Per Sørensen P6.186 Patients with RRMS Who Had an Inadequate Response to a Prior Therapy Demonstrated Durable Improvement in EDSS Functional Systems Scores Over 5 Years with Alemtuzumab — Christopher LaGanke, Regina Berkovich, Oscar Fernandez, Edward Fox, Heinz Wiendl, David Margolin, Karthinathan Thangavelu, Gavin Giovannoni P6.187 Evaluating the Safety and Efficacy of Transitioning Multiple Sclerosis Patients from Natalizumab to Rituximab —James Stark, Armistead Williams, Saud Sadiq P6.188 4 Years PANGAEA: Long Term Data on Effectiveness and Safety from Patients on Natalizumab Switching to Fingolimod in Real World —Tjalf Ziemssen, Holger Albrecht, Judith Haas, Luisa Klotz, Michael Lang, Chrstoph Lassek, Stephan Schmidt, Bjorn Tackenberg, Christian Cornelissen P6.189 Predictive Value of Early MRI Measures for Long-Term Disease Activity in Patients with Relapsing-Remitting Multiple Sclerosis Receiving IFN β-1a SC Tiw or IFN β-1a IM Qw: Post Hoc Analyses of the EVIDENCE Study —Patricia Coyle, Mark Freedman, Fernando Dangond, Juanzhi Fang, Anthony Reder P6.190 MRI Frequency and No Evidence of Disease Activity Status Among Patients with RRMS Receiving IFN β-1a SC Tiw or IFN β-1a IM Qw: Post Hoc Analyses of EVIDENCE —Anthony Reder, Mark Freedman, Juanzhi Fang, Fernando Dangond, Patricia Coyle P6.191 Effects of Multiple Sclerosis Therapies on the Gut Immune System — Katja Thomas, Tjalf Ziemssen, Judith Eisele, Heinz Reichmann P6.192 Dimethyl Fumarate-Associated Lymphopenia in Clinical Practice: Implications for Disease Modifying Therapy Selection —Jessica Robb, Megan Hyland, Lawrence Samkoff Behavioral and Cognitive Neurology: Assessment Tools P6.193 Cerebrovascular Risk Factors and Depression: Report from National Ambulatory Medical Care Survey 2002-2009 —Hossam Egila, Basit Rahim, Muhammad Suri, Adnan Qureshi P6.194 Validation of the AWOL Tool: A Delirium Prediction Rule —Ethan Brown, S. Josephson, Vanja Douglas P6.195 The Neuropsychiatric Inventory Questionnaire (NPI-Q2): Comparative Data in Alzheimer Disease, Lewy Body Dementia, and Frontotemporal Degeneration —Lydia Hatfield, Jennifer Taylor, James Bateman, Matthew Harris, Daniel Kaufer P6.196 Effect of a Comprehensive Inpatient Delirium Care Pathway on Incidence and Length of Stay —Ethan Brown, S. Josephson, Noriko Anderson, Mary Reid, Vanja Douglas P6.197 Durability of Symptom Reductions Associated with Use of HIRREM by Military Personnel with Traumatic Stress —Charles Tegeler, Catherine Tegeler, Jared Cook, Lindsay Howard, Sung Lee, Hossam Shaltout P6.198 Perioperative Rivastigmine Patch Reduces Occurrence of Postoperative Delirium in Elderly at Risk for Dementia —Youn Young Chul, Ha Yong- Chan, Byung-Sun Choi P6.199 Is Olanzapine Predicted to Have Antidepressant Effects on Juvenile Rats in the Forced Swim Test (FST)?— Alicia Cho, Erica Stanley, David Middlemas P6.200 Lesion-Related Delusional Misidentification Syndromes: A Review of All Reported Cases —Richard Darby, Sashank Prasad P6.201 Voxel-based Morphometry of Patients with Schizophrenia and Schizoaffective Disorders —Johnathon Shaffer, Jeiran Choupan, Bryan Mowry, Zhengyi Yang, David Reutens P6.202 Involvement of Subthalamic Neurons in Valence Processing and Impulsivity in Parkinson’s Disease —Justin Rossi, Jonathan Shute, Rene Molina, Enrico Opri, Oscar Castellanos, Corinna Peden, Kelly Foote, Aysegul Gunduz, Michael Okun Behavioral and Cognitive Neurology: Brain-behavior Correlations P6.203 Delayed Post Hypoxic Leukoencephalopathy Following Benzodiazepine and Opiate Overdose: A Case Report and Review of Disease Pathophysiology —Dionne Swor, Frank Sharp, Glen Jickling, Benjamin Koo P6.204 Verbal Memory and Processing Speed Deficits in Middle-Aged Individuals with Type 2 Diabetes Mellitus — María Beatriz Jurado, Michael Palacios, Ibeth Regato-Ugalde, Carlos Cevallos, Ximena Gamboa, Daniel Moreno-Zambrano, Carlos Peñaherrera, María Carolina Duarte, Leonardo Tamariz, Rocío Santibáñez P6.205 Cognitive Reserve in Primary Age-Related Tauopathy —Kyra Jefferson- George, Edward Lee, David Wolk, Corey McMillan P6.206 Digital Versus Paper Self- Administered Gerocognitive Examination (SAGE) —Douglas Scharre, Shu-Ing Chang, Haikady Nagaraja, Nicole Vrettos P6.207 Reduced Tactile Pressure Perception with Age —Tigran Kesayan, Damon Lamb, John Williamson, Adam Falchook, Kenneth Heilman P6.208 Hyperfamiliarity in Dementia and Mild Cognitive Impairment —Simon Kang Seng Ting, Wahab Hameed, Kathryna Kwok, Christopher Gabriel, Kinjal Doshi, Sze Yan Tay, Stephanie Fook-Chong, Sharon Koh, Way Inn Koay P6.209 Encephalitis in the Elderly: NMDA-R Encephalitis Mistaken for Dementia —Ashhar Ali, Eric Baron P6.210 Knowledge Translation in Right Brain Rehabilitation: A Feasibility Study of Prism Treatment After Acute Stroke —A. Barrett, Peii Chen, Kimberly Hreha, Florence Alban, Cynthia Gocon, Christopher Santos, Kevin Lawless, Jennifer LaRosa 138 2016 AAN Annual Meeting Abstract Listing
Presenters Stand by Posters 4:00 p.m.–5:30 p.m. Behavioral and Cognitive Neurology: Clinical Syndromes P6.211 Title: Neuropsychological Functions In People with Juvenile Myoclonic Epilepsy-A Hospital Based Study —Kiran Bala, Preeti Singla, Vibha Sharma P6.212 Associations Among Rapid Bedside Anti-Saccade Assessment and Cognitive Function in Children with Craniopharyngioma —Raja Khan, Heather Conklin, Ashford Jason, Kathryn Russell, Zsila Sadighi, Thomas Merchant P6.213 A Cognitive Screening Tool for ALS Patients: The ALS-FTD-Cog, Preliminary Results —Emma Beeldman, Rosanne Govaarts, Joost Raaphorst, Rob De Haan, Yolande Pijnenburg, Ben Schmand, Marianne De Visser P6.214 Adjunctive Extended-Release Molindone (SPN-810) to Manage Impulsive Aggression in Children with Attention Deficit/Hyperactivity Disorder (ADHD) Receiving Optimized Stimulant Monotherapy and Behavioral Therapy — Scott Brittain, Jennifer Stocks, Janet Johnson, Tesfaye Liranso, Robert Findling P6.215 A Pilot Study of Adaptive Brain Gaming in Cognitively Impaired Older Adults —Jordan Stiver, Matt Wynn, Peter Pressman, Rowan Saloner, Shubir Dutt, Joel Kramer P6.216 Transient Global Amnesia: Clinical Features and Recurrence Prognostic Factors —Lucas Alessandro, Ismael Calandri, Marcos Fernandez Suarez, Lucila Heredia, Mauricio Farez, Ricardo Allegri P6.217 Aphasia, Apraxia and Neglect Due to Stroke in the Light of the "Dual- Loop-Model" —Cornelius Weiller, Lena- Alexandra Beume, Andrea Dressing, Dorothe Kümmerer, Markus Martin, Mariachristina Musso, Roza Umarova, Roza Umarova, Magnus Vry, Michel Rijntjes P6.218 An Elderly Woman Found Wandering Naked in the Street: Cerebral Amyloid Angiopathy-Related Inflammation Causing Acute Reversible Altered Mental Status (A Case Report) — Rahul Shah, Li Xaingping P6.219 Cerebral Amyloid Angiopathy Presenting As New Onset Refractory Status Epilepticus(NORSE), Complicated by Psychosis, Dysautonomia and Posterior Reversible Encephalopathy Syndrome(PRES) —Apoorv Prasad, Sameer Sharma, Elena Schmidt, Julius Latorre P6.220 Validation of a Nurse-Based Delirium Screening Tool for Hospitalized Patients —Anita Hargrave, James Bourgeois, Jesse Bastiaens, S. Josephson, Julia Chinn, Melissa Lee, Jacqueline Leung, Vanja Douglas Aging and Dementia: Neuropathology P6.221 High Prevalence of Co- Morbidity in Pathologically Confirmed Alzheimer Disease in a Canadian Regional Brain Biobank —Michael Marnane, Shervin Mortazavi, Jennifer Li, Angela Kim, Connor Keller, Ian R.A. Mackenzie, Ging-Yuek Hsiung P6.222 Vascular Pathology Is Associated with Rate of Cognitive Decline Independent of AD Pathology (Einstein Aging Study) —Ali Ezzati, Cuiling Wang, Richard Lipton, Dorothea Altschul, Mindy Katz, Dennis Dickson, Carol Derby P6.223 Sensitivity, Specificity and Reliability of Three Pathological Criteria for Alzheimer’s Disease —Alexis Steinberg, Oscar Lopez, Julia Kofler, James Becker, Robert Sweet, Sarah Berman, Eric McDade, Eric Rodriguez, William Klunk P6.224 Pathologies Underlying Longitudinal Cognitive Decline in Old Age —Madeline Nguyen, Nora Mattek, Hiroko Dodge, Randy Woltjer, Diane Howieson, Lisa Silbert, Scott Hofer, Jeffrey Kaye, Andrea Piccinin, Deniz Erten-Lyons P6.225 Neuropathological Influences on the Clinical Phenotype of Synucleinopathies —David Irwin, Murray Grossman, Daniel Weintraub, Howard Hurtig, John Duda, Oscar Lopez, Julia Kofler, Peter Nelson, Randall Woltjer, Joseph Quinn, Jeffrey Kaye, James Leverenz, Debby Tsuang, Katelan Longfellow, Walter Kukull, C. Dirk Keene, Thomas Montine, Cyrus Zabetian, John Trojanowski P6.226 Globular Glial Tauopathy Presenting As Semantic Variant PPA — Jonathan Graff-Radford, Keith Josephs, Joseph Parisi, Dennis Dickson, Caterina Giannini, Bradley Boeve P6.227 Neuroinflammation Promotes Reduced Neurogenesis in Patients with Amyotrophic Lateral Sclerosis (ALS) — Sebastian Peters, Sabrina Kuespert, Eva Zitzelsperger, Rosmarie Heydn, Markus Riemenschneider, Ludwig Aigner, Tim-Henrik Bruun, Ulrich Bogdahn P6.228 Microglial Morphology Is Not Altered by the Presence of RAN Proteins in the Cerebellar Cortex of ALS Patients —Matthew Cykowski, Suzanne Powell, Joan Appel, Ellen Chang, Stanley Appel P6.229 Quantitative Analysis of Detergent-Insoluble Brain Proteinaceous Aggregates and Their Correlation with Semi-Quantitative Staging —Ho-Yann Jong, Deniz Erten-Lyons, Hiroko Dodge, Jeffrey Kaye, Lisa Silbert, Randall Woltjer Aging and Dementia: Lewy Body Dementia and Synucleinopathies P6.230 Accuracy of Clinical Diagnosis of Dementia with Lewy Bodies: A Systematic Review and Meta-Analysis — Simona Arcuti, Giovanni Rizzo, Massimiliano Copetti, Maria Alessandria, Rodolfo Savica, Giancarlo Logroscino P6.231 Clinical Features Predict Lewy Body Pathology and Differentiate Between Different Pathologies: A Clinical- Pathologic Prospective Study —Rodolfo Savica, Thomas Beach, Hent Joseph, Geidy Serrano, Lucia Sue, Brittany Dugger, Holly Shill, Erika Driver-Dunckley, John Caviness, Sandra Jacobson, Shyamal Mehta, Christine Belden, Kathryn Davis, Marwan Sabbagh, Charles Adler P6.232 AD-Related Pathology and Gray Matter Atrophy Rates in Probable Dementia with Lewy Bodies —Lidia Sarro, Matthew Senjem, Emily Lundt, Scott Przybelski, Timothy Lesnick, Bradley Boeve, Val Lowe, David Knopman, Giancarlo Comi, Massimo Filippi, Ronald Petersen, Clifford Jack, Kejal Kantarci P6.233 Olfactory Function in Amnestic and Non-Amnestic Mild Cognitive Impairment Compared with Alzheimer’s Disease Dementia and Dementia with Lewy Bodies —Erin Golden, Jeremiah Aakre, Emily Lundt, David Jones, Jonathan Graff-Radford, Rodolfo Savica, Tanis Ferman, Erik St. Louis, Michael Silber, Mary Machulda, Julie Fields, Neill Graff-Radford, David Knopman, Ronald Petersen, Bradley Boeve P6.234 Initial Patterns and Correlates of Quality of Life in Dementia with Lewy Bodies —Melissa Armstrong, Erin Monari, Leonardo Almeida, Nikolaus McFarland, Irene Malaty, Michael Okun P6.235 An Investigation of White Matter Hyperintensities in Probable Dementia with Lewy Bodies —Lidia Sarro, Christopher Schwarz, Jonathan Graff- Radford, Nirubol Tosakulwong, Robert I. Reid, Scott Przybelski, Timothy Lesnick, Samantha Zuk, Bradley Boeve, Tanis Ferman, David Knopman, Giancarlo Comi, Massimo Filippi, Ronald Petersen, Clifford Jack, Kejal Kantarci P6.236 Clinical-Imaging-Pathologic Analysis in Seven Patients with Dementia: Correlations with Ioflupane SPECT Findings —Bradley Boeve, Val Lowe, Kejal Kantarci, Joseph Parisi, Dennis Dickson, Tanis Ferman, David Jones, Jonathan Graff- Radford, Rodolfo Savica, Mary Machulda, Julie Fields, Christina Dheel, Laura Allen, Daniel Drubach, Erik St. Louis, Michael Silber, Clifford Jack, David Knopman, Ronald Petersen P6.237 Autonomic Dysfunction in Dementia with Lewy Bodies, a Case Series —Melissa Heiry, Melissa Cortez P6.238 Expression of Proteinopathies in the Skin: Alpha-synuclein in Cells Derived from the Neural Crest and in Parkinson Disease —Ildefonso Rodriguez- Leyva, Maria Jimenez-Capdeville, Erika Chi-Ahumada, William Eng, Sami Saikaly, Juan Carrizales-Rodriguez, Juan Castanedo- Cazares, Robert Norman P6.239 Assistant Director —Tracy Cole, Katrina Paumier, Hien Zhao, Andreas Weihofen, Holly Kordasiewicz, Eric Swayze Frontotemporal Dementia and Amyotrophic Lateral Sclerosis P6.240 Clinical and Neuroanatomical Characteristics of Individuals with Frontotemporal Dementia and the C9orf72 Repeat Expansion —Jaya Padmanabhan, Sara Makaretz, Christina Caso, Kathleen Kelly, Michael Brickhouse, Diane Lucente, Bradford Dickerson P6.241 Clinical Markers of Frontal Tau Pathology in 4-Repeat Tauopathies — Jessica Weinstein, Corey McMillan, David Irwin, John Trojanowski, Murray Grossman P6.242 Emotion Network Breakdown Relates to Baseline Autonomic Dysfunction in Behavioral Variant Frontotemporal Dementia —Virginia Sturm, Jesse Brown, Alice Hua, Sandy Lwi, Howard Rosen, Bruce Miller, Robert Levenson, William Seeley P6.243 Major Depression Disorder with a Late Age-of-Onset As a Biological Model to Detect the Brain Features of Depression in Alzheimer's Disease and Behavioral Variant of Frontotemporal Dementia —Elisa Canu, Federica Agosta, Gorana Mandic-Stojmenovic, Ana Munitza, Tanja Stojkovic, Massimiliano Copetti, Elka Stefanova, Dusica Lecic Tosevski, Vladimir Kostic, Massimo Filippi P6.244 Cognition and Social Cognition in Amyotrophic Lateral Sclerosis in an Argentinean-Cohort. Preliminary Data — Federico Nahas, Bruno de Ambrosi, Ismael Calandri, Fernanda Tapajoz, Patricia Zanuzo, Martin Nogues, Ricardo Allegri P6.245 Cognitive Reserve Is Protective of Cognition and Frontal Grey Matter in Amyotrophic Lateral Sclerosis —Katerina Placek, Kylie Ternes, Christopher Olm, Lauren Massimo, John Woo, Lauren Elman, Leo McCluskey, David Irwin, Murray Grossman, Corey McMillan P6.246 Frontotemporal Dementia (FTD) with Late-Onset Obsessive-Compulsive Symptoms (OCs): An Individual-Patient Data Meta-Analysis —Rodrigo Santibanez, Amir Sepehry, Howard Feldman, Ging-Yuek Hsiung P6.247 Progression of Brain Atrophy and Cognitive Impairment in Hereditary Frontotemporal Lobar Degeneration — Salvatore Spina, Howie Rosen, Adam Staffaroni, Luke Bonham, Suneth Attygalle, John Kornak, Joel Kramer, Bruce Miller, Suzee Lee P6.248 Conversational Laughter in the Behavioral Variant of Frontotemporal Dementia —Peter Pressman, Michaela Simpson, Maria Luisa Mandelli, Edoardo Spinelli, Suzie Shdo, Bruce Miller, Jennifer Merrilees, Maria Gorno Tempini, Robert Levenson P6.249 Myelin Oligodendrocyte Basic Protein and Longitudinal Decline in Behavioral-Variant Frontotemporal Degeneration —Lauren Massimo, Lior Rennert, Sharon Xie, Vivianna Van Deerlin, David Irwin, Corey McMillan, Murray Grossman Electrophysiology in Neuromuscular Diseases P6.250 Clinical and Electrophysiological Characteristics of MuSK-MG Patients in Korea —Mun Kyung Sunwoo, Sook Young Roh, Hyun-Jeung Yu, Eun Hye Jeong, Byung-Su Kim, Hyun-soon Jang Thu · April 21 Fast and easy registration · AAN.com/view/AM16 139
Page 1 and 2:
NEW! Dates • Format • Value SCI
Page 3 and 4:
See the value! 2015 Meeting Price 2
Page 5 and 6:
What’s Inside Table of Contents I
Page 7 and 8:
Meeting! INTRODUCTION See You in Va
Page 9 and 10:
Additional Information INTRODUCTION
Page 11 and 12:
OVERVIEWS Mon April 18 Tue April 19
Page 13 and 14:
Schedule Planning Forms Use the con
Page 15 and 16:
My Friday $ A registration fee is r
Page 17 and 18:
Hot Topics Plenary Session Friday,
Page 19 and 20:
$ A registration fee is required L
Page 21 and 22:
Meeting Schedule 6:30 a.m.-8:30 a.m
Page 23 and 24:
Poster Session Schedule and Floorpl
Page 25 and 26:
Meeting Schedule P1.029 Efficacy an
Page 27 and 28:
Presenters Stand by Posters 5:30 p.
Page 29 and 30:
Page 31 and 32:
Page 33 and 34:
Page 35 and 36:
New Faculty and Trainee Reception!
Page 37 and 38:
Meeting Schedule 11:30 a.m.-6:30 p.
Page 39 and 40:
Saturday, April 16 1:00 p.m.-3:00 p
Page 41 and 42:
Meeting Schedule 1:00 p.m.-5:30 p.m
Page 43 and 44:
Page 45 and 46:
Page 47 and 48:
Meeting Schedule 6:30 a.m.-7:15 a.m
Page 49 and 50:
Page 51 and 52:
Page 53 and 54:
Page 55 and 56:
Page 57 and 58:
Page 59 and 60:
Sunday, April 17 Scientific Platfor
Page 61 and 62:
Page 63 and 64:
I5 1:00 p.m.-5:30 p.m. Integrated N
Page 65 and 66:
Opening Party Experience New Ways t
Page 67 and 68:
Page 69 and 70:
Don’t Forget to Visit the Exhibit
Page 71 and 72:
Page 73 and 74:
Page 75 and 76:
Page 77 and 78:
Page 79 and 80:
P3.391 The Quix Test: A 30 Second T
Page 81 and 82:
Annual Meeting App Now Available Th
Page 83 and 84:
Meeting Schedule 9:00 a.m.-11:30 a.
Page 85 and 86:
Page 87 and 88:
I8 1:00 p.m.-5:30 p.m. Integrated N
Page 89 and 90: Industry Therapeutic Updates Indust
Page 91 and 92: $ A registration fee is required L
Page 93 and 94: Meeting Schedule 6:30 a.m.-8:30 a.m
Page 95 and 96: Presenters Stand by Posters 5:30 p.
Page 103 and 104: Frontiers in Neuroscience Plenary S
Page 105 and 106: Meeting Schedule 1:00 p.m.-3:00 p.m
Page 125 and 126: Clinical Trials Plenary Session Wed
Page 131 and 132: Scientific Platform Sessions Meetin
Page 133 and 134: My Thursday $ A registration fee is
Page 139: Presenters Stand by Posters 4:00 p.
Page 145 and 146: Neurology Year in Review Plenary Se
Page 149 and 150: 1:00 p.m.-5:30 p.m. Integrated Neur
Page 151 and 152: New Date and Time: CLOSING PARTY HA
Page 159 and 160: Association of Indian Neurologists
Page 161 and 162: Potamkin Prize for Research in Pick
Page 163 and 164: Cool An AAN initiative to help buil
Page 165 and 166: Closing Party Happy Hour Thursday,
Page 167 and 168: Annual Meeting Attendee Pricing: Go
Page 169 and 170: Disclaimers/Disclosures Disclaimer
Page 171 and 172: Hotel Reservations Why Book a Hotel
Page 173 and 174: Sitka Sq Abbott St Ontario St Ontar
Page 175 and 176: Luggage Restrictions for carry-on b
Page 177 and 178: 68 th Annual Meeting Exhibitors as
Page 179 and 180: 68 th Annual Meeting Planning Meeti
Page 181 and 182: Jonathan S. Katz, MD Jori Fleisher,
Page 183 and 184: AAN Leadership University courses a
show all

NEW!

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?